Takahashi Yoshiyuki, Nishio Nobuhiro
Department of Pediatrics, Nagoya University Graduate School of Medicine.
Center for Advanced Medicine and Clinical Research, Department of Advanced Medicine, Nagoya University Hospital.
Rinsho Ketsueki. 2023;64(9):1184-1191. doi: 10.11406/rinketsu.64.1184.
Chimeric antigen receptor transgenic T cell (CAR-T) therapy targeting the CD19 antigen was approved for relapsed/refractory acute lymphocytic leukemia in the United States in 2017 and in Japan in 2019. Despite the excellent efficacy of CAR-T therapy, the relapse rate is about 50%. To reduce this rate, it will be important to examine predictive factors for relapse and which patients should receive hematopoietic cell transplantation. In addition, as the high cost of CAR-T cells has become a financial toxicity that threatens the health insurance system in many countries, development of less expensive CAR-T products using non-viral vectors is also underway.
靶向CD19抗原的嵌合抗原受体转基因T细胞（CAR-T）疗法于2017年在美国、2019年在日本被批准用于复发/难治性急性淋巴细胞白血病。尽管CAR-T疗法疗效显著，但复发率约为50%。为降低这一比率，研究复发的预测因素以及哪些患者应接受造血细胞移植将很重要。此外，由于CAR-T细胞的高成本已成为一种财务毒性，威胁到许多国家的医疗保险系统，使用非病毒载体开发成本更低的CAR-T产品的工作也在进行中。
